Objective：To explore the feasibility and the efficacy of radical gastrectomy plus implantation of fluorouracil sustained release for  stage Ⅲ gastric carcinorma.
Methods：Clinical materials of 188 cases of stage Ⅲ gastric cancer patieats treated in the First Affiliated Hospital, Nanchang University, from December 2008 to November 2009 were analyzed retrospectively. All cases underwent radical gastrectomy.The patients were randomly divided into two groups:Treatment (A) group, fluorouracil sustained release was implanted intraoperatively(n=96); control (B) group, fluorouracil sustained release was not used (n=92). At 4 weeks after surgery, intravenous chemotherapy was given and they were followed up.
Results：There were no obivious side-effects and complications in group A, except for more abdominal drainage,abdominal pain(78.1%) and low-grade fever(31.3%) than those in group B. The 1 year recurrence rate(6.30%) in group A was much lower than that of group B(16.30%) (P＜0.05), and the 1 year death rate(3.02%) of group A was much lower than that of group B(10.08%) (P＜0.05), respectively.
Conclusions：Implanting fluorouracil sustained release at operation is safe and feasible. It can decrease the postoperative recurrence rate and improve the postoperative survival rate of patients with stage Ⅲ gastric cancer.